Novel Therapeutic Concepts for Complex Femoropopliteal Lesions Using the Jetstream Atherectomy System
Journal of Endovascular Therapy · 2024-12 · 31 (6) · 1218-1226
DOI: 10.1177/15266028231161246 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Endovascular Therapy, online erschienen am 24.03.2023. Verfasst von Dalibor Dukic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology & Vascular Medicine, Fürst-Stirum-Klinik Bruchsal, Bruchsal, Germany. Hauptthemen laut MEDLINE: Popliteal Artery, Peripheral Arterial Disease, Femoral Artery, Atherectomy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
The presence of severe arterial calcification is associated with less favorable outcomes in terms of procedural and clinical success as well as higher rates of major adverse limb events. Recent studies incorporating rotational atherectomy for effective preparation of severely calcified lesions demonstrate beneficial procedural outcomes by obtaining maximal luminal gain and improved long-term outcomes.
Methods
This prospective single-center, observational study includes patients with severely calcified femoropopliteal lesions with chronic limb ischemia Rutherford 1–5 between January 2017 and July 2019, who underwent atherectomy using the Jetstream Atherectomy system, followed by drug-coated balloon angioplasty. Lesion calcification was categorized by the Peripheral Arterial Calcium Scoring System (PACSS), whereas lesion complexity was classified by the Transatlantic Inter-Society Consensus (TASC). Safety and efficacy aspects in terms of vessel injury, thromboembolism, and clinical success were systematically analyzed up to 12 months of follow-up (FU).
Results
In 162 consecutive patients, 210 non-stented and 22 stented lesions were treated. Twelve (7.4%) patients received bail-out stenting. Mean lesion length was 24.2±4.8 cm; 51% were chronic total occlusions (mean occlusion length 18.2±5.1 cm). TASC C lesions were present in 38 patients (23.5%) and TASC D lesions in 124 patients (76.5%). The mean PACCS score was 3.3±0.9. Device success was achieved in 88%; procedural success was noted in 99% of the lesions. Embolic protection device was used in 11.7%. Perforation or dissection occurred in none of the cases. Asymptomatic peripheral embolization was noted in 10 patients (6.2%). Clinical FU at 12 months was available in 157 of 162 patients (96.9%). At 12 month FU, (1) mean Rutherford classification at baseline of 3.7±0.6 significantly dropped to 1.0±0.9 (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology & Vascular Medicine, Fürst-Stirum-Klinik Bruchsal, Bruchsal, Germany.
- Vascular Centre, Klinikum Arnsberg, Arnsberg, Germany.
- Department of Angiology, University of Graz, Graz, Austria.
- Department of Surgery, University Hospital Munich, Munich, Germany.
- Department of Cardiology & Vascular Medicine, GRN Hospital Weinheim, Weinheim, Germany.
Zitieren
APA
Dukic, D., Martin, K., Lichtenberg, M., Brodmann, M., Andrassy, J., Korosoglou, G., & Andrassy, M. (2024). Novel Therapeutic Concepts for Complex Femoropopliteal Lesions Using the Jetstream Atherectomy System. Journal of Endovascular Therapy, 31(6), 1218-1226. https://doi.org/10.1177/15266028231161246
Vancouver
Dukic D, Martin K, Lichtenberg M, Brodmann M, Andrassy J, Korosoglou G, et al. Novel Therapeutic Concepts for Complex Femoropopliteal Lesions Using the Jetstream Atherectomy System. Journal of Endovascular Therapy. 2024;31(6):1218-1226. doi:10.1177/15266028231161246
BibTeX
@article{Dukic2024,
author = {Dukic, Dalibor and Martin, Klaus and Lichtenberg, Michael and Brodmann, Marianne and Andrassy, Joachim and Korosoglou, Grigorios and Andrassy, Martin},
title = {Novel Therapeutic Concepts for Complex Femoropopliteal Lesions Using the Jetstream Atherectomy System},
journal = {Journal of Endovascular Therapy},
year = {2024},
volume = {31},
number = {6},
pages = {1218--1226},
doi = {10.1177/15266028231161246}
}
EUVIMED